New Cervical Cancer Pill Shows Promise in Clinical Trials

A new cervical cancer pill has shown significant promise in early trials by effectively preventing HPV from triggering cancerous cell mutations.

The ICMR has successfully transferred indigenous biomedical technologies for this treatment and related vaccines to major pharmaceutical firms like Emcure and Biological E.

These advancements represent a major step forward in India's fight against cervical cancer, aiming to make life-saving treatments more accessible and affordable.